Key study of Ketek drug may have included fraud, errors

05/1/2006 | Wall Street Journal, The

Sanofi-Aventis' respiratory infection drug Ketek has been linked to reports of severe liver damage, and now some documents are raising questions about possible fraud and errors in a clinical trial of the drug that was used in the application for FDA approval. The drug company defended the clinical trial and said Ketek is safe.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC